Clinical Trials Browser

NCT03155620 2026-04-14

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT02893917 2026-04-13

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Phase 2 Active not recruiting

90 enrolled 19 charts

Genitourinary

Prostatic Neoplasms

NCT03660826 2026-04-13

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

NCT03953898 2026-04-13

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Phase 2 Active not recruiting

14 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Active not recruiting

61 enrolled 15 charts

Gynecologic

Fallopian Tube Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT03878095 2026-04-08

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Phase 2 Active not recruiting

24 enrolled 12 charts

Gastrointestinal

Cholangiocarcinoma

NCT03787680 2026-03-23

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2 Active not recruiting

49 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Breast

Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Phase 2 Active not recruiting

70 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

KEYLYNK-009

AMTEC IIT: Phase 2 Multiarm Study in TNBC

ORION

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

BAYOU

CUPISCO

HUDSON

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

337

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Pembrolizumab and Olaparib in Cervical Cancer Patients

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

BAROCCO

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

COMETABreast

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

A Study of Olaparib and Durvalumab in Prostate Cancer

ICEBERG 1

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

OLAPCO

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

CONCERTO